Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL715802 | 1.00 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL3657 | 1.00 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL276988 | 1.00 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL11060179 | 1.00 | CA4 (1.00) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL25212993 | 0.97 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL6690080 | 0.97 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL10692975 | 0.97 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL21694724 | 0.97 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL20917176 | 0.97 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL10692967 | 0.97 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218291-A1 | CONTACT LENS TREATING SOLUTION | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-07-04 | — | — | US | claimed |
| CN-109897724-A | Nutrition acer truncatum edible oil and its preparation process | 贵州中志浩宝枫健康产业技术开发有限公司 | 2019-06-18 | — | — | CN | claimed |
| CN-106113965-A | A kind of alcohol-free fountain solution containing composite buffer system and preparation method thereof | 合肥环照高分子材料厂 | 2016-11-16 | — | — | CN | claimed |
| US-20130115300-A1 | CIPROFLOXACIN DRY SYRUP COMPOSITION | S. ZHAVERI PHARMAKEM PVT. LTD., (IN) | 2013-05-09 | — | — | US | claimed |
| EP-2558079-A1 | CIPROFLOXACIN DRY SYRUP COMPOSITION | S. Zhaveri Pharmakem PVT. Ltd (IN) | 2013-02-20 | — | — | EP | claimed |
| CN-101556281-B | Biological detection method of PPAR active pollutant | UNIV HUAZHONG SCIENCE TECH | 2012-12-05 | — | — | CN | claimed |
| WO-2011128906-A1 | CIPROFLOXACIN DRY SYRUP COMPOSITION | S. ZHAVERI PHARMAKEM PVT. LTD. (IN) | 2011-10-20 | — | — | WO | claimed |
| CN-101556281-A | Biological detection method of PPAR active pollutant | UNIV HUAZHONG SCIENCE TECH (CN) | 2009-10-14 | — | — | CN | claimed |
| US-20030143259-A1 | For therapy of infections of the eye and surrounding tissues | SUN PHARMACEUTICAL INDUSTRIES, INC | 2003-07-31 | — | — | US | claimed |
| US-20250145722-A1 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE | TRUEBINDING, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2024263621-A2 | PERSONALIZED TOPICAL FORMULATION IMPRINTED WITH QUANTUM ENERGY AND USING AI EXPERT ANALYSIS OPTIMIZATION | LULUBLE INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4351568-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | Mindset Pharma Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| CN-110381986-B | Truncated von willebrand factor polypeptides for extravascular administration to treat or prevent coagulation disorders | 康诺贝林伦瑙有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-112569225-B | Non-drug helicobacter pylori bactericidal composition | 共生地球生物科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-5482836-A | DNA purification by triplex-affinity capture and affinity capture electrophoresis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-01-09 | — | — | US | disclosed |
| EP-0684312-A2 | Preparation process of a natural protein sweetener | URQUIMA S.A. (ES) | 1995-11-29 | — | — | EP | disclosed |
| EP-0439997-B1 | Novel fungal expression system | CIBA GEIGY AG (CH) | 1995-11-08 | — | — | EP | disclosed |
| EP-0439997-A1 | Novel fungal expression system | CIBA-GEIGY AG (CH) | 1991-08-07 | — | — | EP | disclosed |
| US-4749501-A | ENCAPSULATING HYDROPHOBIC LIQUID CORE WITH HYDROPHILIC COLLOID OF GELATIN AND ANIONIC POLYMER | LION CORPORATION (JP) | 1988-06-07 | — | — | US | disclosed |
| US-4601899-A | Hydrous toothpaste containing TiF4 and chelating agent | BEECHAM INC. (US) | 1986-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143259-A1 | For therapy of infections of the eye and surrounding tissues | AZI2, MALT1, PDE6D | CA4 3760/4885CASP1 2008/4885FFAR3 3189/4885 |
| US-20130115300-A1 | CIPROFLOXACIN DRY SYRUP COMPOSITION | TAS2R30, TAS2R10, TAS2R5 | CA4 3084/4885CASP1 3058/4885FFAR3 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.